読み込み中
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
前日終値
$86.06
+$0.05 · +0.06%
日中の時刻はETです。市場データは遅延する場合があります。
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
日中レンジ
現在 $86.06
52週レンジ
現在 $86.06
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
65
割安
センチメント
62
強気
リスク
32
中程度のリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
日中レンジ
現在 $86.06
52週レンジ
現在 $86.06
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$150.4
上昇余地（74.76%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.62億0.01%2.3兆 USD0.03%$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB1.17億0.06%1853億 USD0.03%$288.16-0.46%
iShares Russell 2000 ETFIWM1.07億0.14%787.4億 USD0.19%$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1.04億1.05%103.03億 USD0.35%$151.4-1.54%
Vanguard Morningstar Small-Cap Growth ETFVBK6715.9万0.15%447億 USD0.05%$340.88-1.12%
Vanguard Extended Market ETFVXF5493.16万0.06%954億 USD0.05%$233.52-0.63%
iShares Russell 2000 Growth ETFIWO3769.15万0.27%139.17億 USD0.24%$353.71-0.86%
iShares Biotechnology ETFIBB3546.64万0.33%108.2億 USD0.44%$204.26-1.08%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
